LAUSR

espanolIntroduccion: el principal problema de salud publica en Mexico es la obesidad y sus enfermedades asociadas, incluyendo las bucales. Objetivo: evaluar el efecto del tratamiento con metformina en pacientes obesos de clase I sobre la actividad de las metaloproteinasas presentes en el periodonto con periodontitis cronica. Metodos: se realizo un estudio clinico con 68 pacientes mujeres con obesidad de clase I y enfermedad periodontal. Se dividieron en 4 grupos; a 2 de ellos, ademas del tratamiento periodontal, se les administro metformina de 850 mg al dia durante seis semanas. Se tomaron 2 muestras por paciente de tejido periodontal antes y despues de cada tratamiento y se midio el indice de masa corporal (IMC), el indice de placa dentobacteriana y de inflamacion. Mediante zimografia en gel de acrilamida se midio la actividad de las metaloproteinasas en la muestra de tejido recolectada. Los datos obtenidos fueron analizados mediante estadistica descriptiva t de student para muestras relacionadas y se realizo ANOVA de una via considerando p Resultados: en el grupo de pacientes a las que se les administro metformina al final del tratamiento se observo una disminucion del indice de masa corporal, del grado de inflamacion y menor actividad de metaloproteinasas respecto al grupo control (65% frente a 25%; p Conclusiones: el tratamiento con metformina en pacientes con obesidad de clase I y enfermedad periodontal disminuye el IMC, mejora los sintomas de la periodontitis cronica y disminuye la actividad de las metaloproteinasas 1, 3, 8 y V presentes en el periodonto de estos pacientes. EnglishIntroduction: in Mexico the main problem in public health is obesity and other diseases that are associated whit this condition, including oral health. Objective: to evaluate the effect of metformin treatment in patients with class I obese on the activity of metalloproteinases present in periodontium with chronic periodontitis. Methods: a clinical study was conducted in 68 patients with class I obesity and periodontal disease. They were divided into 4 groups. 2 of them, in addition to the periodontal treatment, were administered metformin 850 mg per day for six weeks; 2 samples were taken per patient of periodontal tissue before and after each treatment, body mass index, plaque index and inflammation were measured. Acrylamide gel zymography was used to measure the activity of metalloproteinases in the sample of tissue collected. The data obtained were analyzed by descriptive statistics, student t for related samples and one-way ANOVA was performed considering p Results: in the group of patients who were administered metformin at the end of the treatment, there was a decrease in the body mass index, the degree of inflammation and lower metalloproteinase activity, compared with the control group (65% vs 25%; Conclusions: treatment with metformin in patients with obesity class I and periodontal disease decreases BMI, improves the symptoms of chronic periodontitis and decreases the activity of metalloproteinases 1, 3, 8, V present in periodontium of these patients.